Peer-reviewed veterinary case report
How clopidogrel affects platelet function in dogs
By Yoon, Eunchae et al.·Published in Frontiers in veterinary science·2025·College of Veterinary Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of clopidogrel impact on canine platelet function using flow cytometry and thromboelastography platelet mapping.
- Species:
- dog
Plain-English summary
Five dogs were given a medication called clopidogrel to see how well it could reduce platelet function, which is important for preventing blood clots. After taking the medication for a week, tests showed that clopidogrel significantly decreased the strength of blood clots formed in response to certain triggers, indicating it was effective in inhibiting platelet activity. The dogs did not show any negative side effects from the treatment, suggesting that clopidogrel is safe for use in dogs. This study supports the use of clopidogrel at a low dose to help manage conditions where reducing blood clotting is necessary.
People also search for: dog blood clot prevention · clopidogrel for dogs · dog platelet function treatment
Abstract
BACKGROUND: Clopidogrel is frequently used in veterinary medicine to therapeutically decrease platelet function, although some different dosages have been published. Therefore, we assessed the antiplatelet effects of the recommended dosage (1 mg/kg PO q24h) on canine platelet function. METHODS: Five dogs were administered either clopidogrel or placebo, with a 14-day washout period. Platelet function was assessed using thromboelastography (TEG) and flow cytometry, complete blood count, and biochemical analyses were performed for clinicopathological evaluation. Blood samples were collected at baseline and 7 days after drug administration. TEG parameters including maximum amplitude and platelet mapping for adenosine diphosphate (ADP)-induced responses were used to monitor therapeutic efficacy. Flow cytometry was used to analyze CD62P expression and platelet activation stimulated by ADP and other agonists. RESULTS: TEG analysis demonstrated a significant reduction in ADP-induced clot strength following clopidogrel administration ( < 0.05), indicating effective platelet inhibition. Flow cytometry confirmed the marked inhibition of platelet activation, with significant decreases in the percentage of CD62P positive platelets and the mean fluorescence intensity under ADP and epinephrine stimulation ( < 0.05). Hematological and biochemical parameters remained stable across all groups, confirming the safety of clopidogrel administration. These findings highlight the efficacy and safety of clopidogrel as an antiplatelet agent in dogs. CONCLUSION: This study confirmed the efficacy of low-dose (1 mg/kg, p.o., q24h) clopidogrel in dogs without a loading dose. TEG and flow cytometry are effective tools for assessing clopidogrel responsiveness in dogs and may aid in optimizing antiplatelet therapy in clinical practice.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40538731/